Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients

Nikoletta Dimitriou*, Evangelos Felekouras, Ioannis Karavokyros, Andreas Alexandrou, Emmanuel Pikoulis and John Griniatsos

Abstract

Background: The incidence of colorectal cancer (CRC) is expected to increase by 80% in year 2035. Even though advantages in treatment of CRC have being made over the last decades, the outcome remains poor. Recently, several inflammatory markers including pretreatment neutrophil to lymphocyte ratio (NLR), have being used as prognostic factors, since host inflammatory response to cancer is believed to determine disease progression. The aim of this study is to evaluate the prognostic significance of pretreatment NLR, in terms of overall survival (OS), 5-year survival, disease-free survival (DFS) and recurrence, in CRC patients who underwent curative resection.

Methods: We retrospectively reviewed 296 patients, who were submitted to elective surgery as first therapeutic option in curative intent, between January 2010 and December 2015. Pretreatment NLR, as well as demographics, clinical, histopathologic, and laboratory data were analyzed. Univariate and multivariate analyses were conducted to identify prognostic factors associated with OS, 5-year survival, DFS and recurrence.

Results: The cutoff point of NLR was calculated with Kaplan-Meier curves and log-rank test to 4.7. Univariate and multivariate analyses disclosed elevated NLR as a significant dismal prognostic factor for DFS (HR 1.88; 95% CI 1.01–3.52; p = 0.048), 5-year survival (HR 2.14; 95% CI 1.12–4.10; p = 0.021) and OS (HR 2.11; 95% CI 1.11–4.03; p = 0.023). In a subgroup analysis, in patients with stage II CRC, NLR > 4.7 was a stronger poor predictor for DFS (HR 2.76; 95% CI 1.07–7.13; p = 0.036), 5-year survival (HR 3.84; 95% CI 1.39–10.63; p = 0.01) and OS (HR 3.62; 95% CI 1.33–4.82; p = 0.012). After adjusting stage for gender, age, location of the primary tumor, differentiation, as well as the presence of perineural, vascular, and lymphovascular invasion, the significance of NLR > 4.7 became more prominent for DFS (HR 2.85; 95% CI 1.21–6.73; p = 0.0176), 5-year survival (HR 4.06; 95% CI 1.66–9.93; p = 0.002) and OS (HR 4.07; 95% CI 1.69–9.91; p = 0.002) in stage II patients.

Conclusion: Pretreatment NLR > 4.7 is a poor prognostic factor for DFS, 5-year survival and OS in CRC patients undergoing curative resection. The dismal prognostic effect of NRL is magnified in Stage II CRC patients.

Keywords: Colorectal cancer, Prognosis, Inflammatory markers, Neutrophil to lymphocyte ratio, Survival
Background

The “classical model” of colorectal carcinogenesis is from normal mucosa to adenoma, then to dysplasia and then to cancer, the so-called “adenoma-carcinoma sequence” [1]. The molecular sequence of the above events include early loss of regulation of the Wnt signaling pathway, accumulation of activating mutations in onco-genes such as KRAS and BRAF, mutations in TP53 and SMAD4 genes and chromosomal instability, finally leading to malignant transformation [2].

Inflammation is currently considered as a hallmark for cancer development [3]. Current evidence addresses that within a tumor tissue and beside cancer cells, host structures (e.g. extracellular matrix), non-immune cells (e.g. fibrous tissue cells) and immune cells namely eosinophils, basophils, mast cells, lymphocytes, natural killer cells and dendritic cells [4–6], interact and contribute to a highly immunosuppressive microenvironment [7]. Lymphocytes have a crucial role in this microenvironment, since progressive increase in tumor-infiltrating lymphocytes is directly correlated with antitumor activity [8]. Intratumoral inflammation is assessed in hematoxylin and eosin stained tissue sections of formalin-fixed paraffin-embedded tumor specimens, scoring the average of chronic inflammation cells density within neoplastic cells’ area.

On the other hand, tissue hypoxia and necrosis [9] can cause complex interactions between the tumor and the nonspecific host inflammatory response, finally favoring disease’s progression in cancer [10]. That systemic inflammatory response involves alterations in neuroendocrine and hematopoietic system, in protein and energy metabolism and in liver function. Hepatocytes synthesize and release into the systemic circulation acute-phase proteins which are associated with lymphocytopenia and impaired T lymphocytic response within the tumor, compromising cell-mediated immunity [11]. A dysregulated systemic inflammatory response promotes cancer progression [12], while the presence of a systemic inflammatory response is associated with reduced survival [11]. For systemic inflammatory response estimation, serum levels of white blood cells, neutrophils, lymphocytes, platelets, C-reactive protein (CRP) and albumin, either alone or in several combinations, have been used as prognostic factors in various malignant solid tumors.

Roxburgh et al [13] disclosed that intratumoral and systemic inflammation are linked through the cell-mediated immune system, further stating that the type, density and location of a variety of immune cells, and not an individual immune cell type, are the important independent determinants of cancer-specific survival in patients with colorectal cancer [14], while Turner et al [15] demonstrated that intratumoral and systemic inflammatory responses appeared to be largely independent of each other.

Comparative analyses of the two inflammatory responses disclosed that when a high-grade intratumoral immune response exists, the longer the survival [14], high tumor infiltration by chronic inflammatory cells combined with low systemic inflammation are correlated to a significantly better prognosis [15], while increased systemic inflammatory response is consistently associated with a poor outcome independently to the tumor stage [16, 17]. Hence, a decreased intratumoral inflammatory response and an increased systemic one might indicate a decreased immunological local control of the tumor, producing a systemic pro-inflammatory environment which facilitates cancer progression [4, 18].

NLR has been proposed as reflecting the balance between pro-tumor inflammation and anti-tumor immune function [19] and its prognostic significance has been extensively studied in several solid tumors [20]. Pronounced intratumoral lymphocytic infiltration has been proposed as a novel independent prognostic factor for colorectal cancer patients, even superior to the Dukes’ staging system [21], while systemic inflammation response may serve as a supplemental index in TNM staging system [22, 23].

The aim of this study was to evaluate the prognostic significance of pretreatment NLR, in terms of overall survival (OS), 5-year survival, disease-free survival (DFS) and recurrence in CRC patients, who underwent curative resection, without neoadjuvant treatment.

Methods

Patients

From 2009 onwards, all patients who were referred to our Department for further investigation and treatment, having been diagnosed with colorectal tumors, were prospectively enrolled. Upon their admission, all patients were informed that their details such as demographics, clinical data, laboratory results, adjuvant or neo-adjuvant therapies, type of operation, postoperative complications, histological findings, follow-up, elapse time to either local or distant recurrence, short and long term outcome as well as survival, will be prospectively collected. All agreed to participate and all consented for free use of their details for scientific purposes (research, presentations, publications, etc) in the future.

Between January 2010 and December 2015, 360 patients suffering from colorectal cancer were submitted to surgery, as first therapeutic option in curative intent, in the 1st Department of Surgery of the University of Athens, in “Laiko” Hospital.

In accordance to the Declaration of Helsinki, the present study was approved by the Scientific Council of the “Laiko” Hospital.

All patients suffered from sporading colorectal cancer and all had undergone colonoscopy and biopsies for
histological confirmation of the disease. For staging of the metastatic disease, they underwent at least computer tomography (CT) of thorax and abdomen. Patients with rectal cancer were further submitted to magnetic resonance imaging (MRI) of the pelvis for loco-regional disease staging [24].

Prior to any therapeutic option implementation, all cases were discussed in the Multi-Disciplinary Cancer meeting (which comprised Surgeons, Oncologists, Radiologists and Pathologists). The most suitable therapeutic strategy was planned and was adopted by all surgeons.

Excluding patients: (i) with uncompleted data (n = 5), (ii) who died within 90 days from the initial operation (n = 6), (iii) who were histologically classified as Tis (n = 355), (iv) who were diagnosed as stage IV, even though a curative resection was achieved (n = 8) and (vi) who suffered from multiple distant metastases (n = 10), a total of 296 adenocarcinoma patients were enrolled in the present study and retrospectively analyzed.

**Hematological tests**

All blood samples were taken within three days before surgery. In this way, any kind of infection and co-existing inflammatory disease could be reliably excluded [25]. NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count.

**Optimal cut-off value for NLR**

In literature, there is an increasing interest in finding the optimal threshold value above which NLR significantly increases the likelihood of death or recurrence [26–30].

This has been typically carried out using ROC curves, which visually represent the sensitivity (i.e. probability of correctly identifying an event e.g. a death) and the specificity (i.e. probability of correctly identifying a nonevent) of various cutoffs. However, main disadvantage of the method is that it cannot distinguish censored from fully observed survival times. Thus, patients who were lost during follow up, were remained throughout calculations, independently if their survival times were censored or not. Hence, failure to take into account the censored times can yield to misleading inferences. In the present study, we used a method [30] based on Kaplan-Meier curves and the logrank test, which do account for censoring. For a range of potential threshold values of NLR, we calculated the Kaplan-Meier curves and the logrank test, selecting the threshold giving the greatest separation of curves in terms of the lowest p-value.

**Oncologic outcome**

The pathological stage of the disease was based on the 7th TNM Classification [31]. The elapsed period from the initial operation to the development of the recurrence, the site and the organ of recurrence, the therapeutic strategies and the final outcome were documented during the follow-up, for DFS and OS estimation.

**Statistical analysis**

Statistical analyses were performed using the STATA statistical package (Version 13.0, Stata Corp, College Station, Texas). Quantitative variables were summarized as median and Interquartile Range (IR) when deviation from normal distribution was observed. Histograms and distribution plots (Percentile-Percentile and Quantile-Quantile plots) were used to evaluate the normality of the quantitative variables. Categorical variables were summarized as absolute and percentage values. Such descriptive statistics were presented for the overall sample, as well as for the NLR category. For quantitative variables, p-values were based on the t-test or the Mann–Whitney U test, if non-normality was seen. Association between categorical variables was measured through Fisher’s exact test. The significance level was pre-determined at 5%.

We used standard Cox proportional hazards models, in order to study the effect of NLR on OS, 5-year survival, DFS and recurrence. Known significant demographic, clinical and tumor characteristics were taken into account to examine whether there is an independent association of NLR with the event of interest.

**Results**

There were 114 female patients with a median age of 71 years (IR 63–79) and 182 male patients with a median age of 72 years (IR 63–77). The clinicopathologic characteristics of the enrolled patients are presented in Table 1.

**Distribution of NLR values among several clinicopathological variables (Table 2)**

The median value of NLR for the whole study population was 2.55 (IR: 1.93–3.41). Statistically significant increased median values of NLR was found among patients older than 72 years old compared to them younger than 72, and in primary tumors in which histology report disclosed perineural and vascular invasion. Moreover, there was a gradually increased median value of NLR from T1 to T4 tumors, (1.88, 2.49, 2.60 and 2.76, respectively) although a statistical significance was not reached under any possible combination. The lowest median NLR value was noticed in Stage I patients. However, a marginally statistically significant difference (p = 0.049) was noticed when stage I patients compared to the aggregated stage II and III patients. Although not statistically significant, we should mentioned that the highest median NLR values were detected among primary tumors positive for perineural invasion (3.45), among patients who developed distant metastases (3.05),
among them who developed recurrence of the disease (2.79) and among N2 patients (2.78).

### Correlation between NLR and several clinicopathological variables

Setting the NLR cut-off value at 4.7, patients were divided in two groups ($\text{NLR} \leq 4.7$, $\text{n} = 260$ and $\text{NLR} > 4.7$, $\text{n} = 36$). Univariate analysis among several clinicopathological variables between the two groups (Table 3), revealed that patients with $\text{NLR} > 4.7$ were most likely of advanced age ($p = 0.004$), elderly than 72 years old ($p = 0.033$), with nearly doubled probability for disease-related death ($p = 0.012$) and worse overall survival ($p = 0.036$), compared to the patients with $\text{NLR} \leq 4.7$.

### Oncologic outcome

Recurrence, DFS, 5-year survival and OS were set as the end points for the oncologic outcome of the patients. Within a median follow up of 45 months (IR 27–68.5), 31 patients developed recurrence of the disease. Fifteen patients developed local recurrence, while the remaining 16 developed distant metastases namely: liver ($\text{n} = 7$), lung ($\text{n} = 3$), simultaneous lung and liver ($\text{n} = 3$) and disseminated peritoneal carcinomatosis ($\text{n} = 3$). Eleven patients who developed local recurrence and 12 patients who developed distant metastases, died from the disease.

Multivariate analyses among factors which might influence recurrence (Table 4) disclosed that stages II and III, as well as vascular invasion were independently related to a worse prognosis. However, NLR was unrelated to the recurrence.

On the other hand (Tables 4 and 5), $\text{NLR} > 4.7$, age above 72 years-old, stages II and III and vascular invasion had independent adverse effect on DFS (Fig. 1), 5-year survival (Fig. 2) and OS (Fig. 3).
Oncologic outcome for stage II patients
Noteworthy, stage II was found as independently related to the DFS ($p = 0.029$) but it did not reach statistically significance regarding recurrence, 5-year survival and OS. Hence, a multivariate analysis among factors which could affect outcome in the 126 stage II patients was conducted (Table 6), disclosing NLR > 4.7 as an independent dismal factor for DFS, 5-year survival and OS, but not for the recurrence itself. After adjusting stage for gender, age, location of the primary tumor, differentiation, as well as the presence of perineural, vascular, and lymphovascular invasion, the significance of NLR > 4.7 became more prominent for DFS, 5-year survival and OS in stage II patients (Table 7).

Discussion
Systematic review [32] and meta-analyses [33–37] agreed that elevated pre-treatment NLR predicts poor prognosis in CRC patients, both in those with localized disease as well as in those with liver metastases.

The exact NLR cut-off value varies among the studies. Among the 19 studies included in a systematic review, in one the cut-off value was set at 4.98 and in eight at 5 [32]. In eight out of 13 (61.5%) studies included in a meta-analysis, the cut-off value had been set at 5 [33], in 11 out of 16 (69%) studies included in another meta-analysis, the cut-off value had also been set at 5 [35], a third meta-analysis which included 15 studies, disclosed that patients with pretreatment NLR < 5 were significantly more likely to have 5-year overall survival and 5-year disease-free survival [36], while in the most recent meta-analysis, in 13 out of 16 (81%) included studies, the cut-off value had been set at 5 [37]. These findings suggest that a value close to 5 seems to provide the most statistically significant results.

In agreement to previous reports, the present study concluded that in patients with localized CRC, an NLR above 4.7 was a dismal prognostic factor for DFS, 5-year survival and overall survival.

However, the exact mechanism explaining the adverse association between NLR and survival outcome in CRC

| Table 2 NLR among several clinicopathological variables |
|-----------------|-----------------|-----------------|
| Parameter       | NLR (Median + IR) | p value |
| Gender          |                 |     |
| Male            | 2.59 (2.05–3.32) | NS   |
| Female          | 2.51 (1.87–3.69) |     |
| Age             |                 |     |
| ≥ 72 years      | 2.72 (2.14–3.76) | 0.016 |
| < 72 years      | 2.41 (1.82–3.16) |     |
| Primary tumor   |                 |     |
| Right colon     | 2.67 (2.13–3.76) |     |
| Left colon      | 2.65 (1.89–3.42) |     |
| Rectum          | 2.48 (1.81–3.08) |     |
| Right VS Left colon | 2.67 (2.13–3.76) VS 2.49 (1.85–3.24) | NS |
| Colon VS Rectum | 2.67 (2.10–3.68) VS 2.48 (1.81–3.08) | NS |
| Differentiation |                 |     |
| Low             | 2.7 (2.2–3.44)   | NS   |
| Medium + High   | 2.51 (1.88–3.4)  |     |
| T               |                 |     |
| T1              | 1.88 (1.53–2.98) | NS   |
| T2              | 2.49 (1.85–3.14) |     |
| T3              | 2.6 (2.0–3.43)   |     |
| T4              | 2.76 (2.27–5.22) |     |
| N               |                 |     |
| N0              | 2.58 (1.92–3.37) | NS   |
| N1              | 2.34 (1.85–3.45) |     |
| N2              | 2.78 (2.29–3.95) |     |
| No of lymph node harvested | |     |
| < 12            | 2.37 (2.09–3.28) | NS   |
| ≥ 12            | 2.58 (1.92–3.43) |     |
| No of infiltrated lymph nodes | |     |
| 0 (n = 198)    | 2.58 (1.96–3.43) | NS   |
| 1 (n = 21)     | 2.22 (1.73–3.82) |     |
| ≥ 2 (n = 77)   | 2.55 (1.91–3.33) |     |
| Stage           |                 |     |
| Stage I         | 2.26 (1.74–2.87) | 0.049 |
| Stage II        | 2.67 (2.16–3.45) |     |
| Stage III       | 2.55 (1.96–3.60) |     |
| Stage I VS Stage II + III | 2.26 (1.74–2.87) VS 2.62 (2.07–3.48) |     |
| Perineural invasion |               |     |
| No              | 2.53 (1.91–3.30) | < 0.001 |
| Yes             | 3.45 (2.24–6.00) |     |
| Vascular invasion |               |     |
| No              | 2.54 (1.91–3.36) | 0.034 |
| Yes             | 2.68 (2.17–4.18) |     |
| Lymphatic invasion |               |     |
| No              | 2.53 (1.91–3.40) | NS   |
Table 3  Univariate analysis between the two groups of patients, after setting the NLR cutoff value at 4.7

| Parameter                      | NLR ≤ 4.7 (n = 260) | NLR > 4.7 (n = 36) | p-value |
|-------------------------------|----------------------|--------------------|---------|
| Gender                        |                      |                    |         |
| Female                        | 96                   | 18                 | NS      |
| Male                          | 164                  | 18                 |         |
| Age (years)                   |                      |                    |         |
| Median + IR                   | 71 (63–77)           | 75.5 (70.5–81)     | 0.004   |
| Age > 72                      |                      |                    |         |
| Age ≤ 72                      | 144                  | 13                 | 0.033   |
| Age > 72                      | 116                  | 23                 |         |
| Primary tumor                 |                      |                    |         |
| Right colon                   | 88                   | 15                 | NS      |
| Left colon                    | 54                   | 8                  |         |
| Rectum                        | 118                  | 13                 |         |
| Differentiation               |                      |                    |         |
| Low                           | 56                   | 7                  | NS      |
| Medium + High                 | 204                  | 29                 |         |
| T                             |                      |                    |         |
| T1                            | 17                   | 1                  | NS      |
| T2                            | 49                   | 8                  |         |
| T3                            | 175                  | 20                 |         |
| T4                            | 19                   | 7                  |         |
| N                             |                      |                    |         |
| N0                            | 165                  | 22                 | NS      |
| N1                            | 68                   | 9                  |         |
| N2                            | 27                   | 5                  |         |
| No of lymph nodes harvested   |                      |                    |         |
| Median + IR                   | 19 (14–27)           | 17 (15–28)         | NS      |
| No of lymph nodes harvested   |                      |                    |         |
| Lymph nodes ≥12               | 230                  | 31                 | NS      |
| Lymph nodes < 12              | 30                   | 5                  |         |
| Stage                         |                      |                    |         |
| Stage I                       | 55                   | 6                  | NS      |
| Stage II                      | 110                  | 16                 |         |
| Stage III                     | 95                   | 14                 |         |
| Perineural invasion           |                      |                    |         |
| No                            | 246                  | 27                 | < 0.001 |
| Yes                           | 14                   | 9                  |         |
| Vascular invasion             |                      |                    |         |
| No                            | 226                  | 27                 | NS      |
| Yes                           | 34                   | 9                  |         |
| Lymphatic invasion            |                      |                    |         |
| No                            | 227                  | 30                 | NS      |
| Yes                           | 33                   | 6                  |         |
| Site of recurrence            |                      |                    |         |
| Distant                       | 12                   | 4                  | NS      |

Dimitriou et al. BMC Cancer (2018) 18:1202
patients, remains unknown. Neutrophilia is a common finding in cancer patients. Colorectal cancer cells secrete granulocyte colony stimulating factor which recruits neutrophils into the tumor site [38]; several among the micro-environment cells produce mediators capable of recruiting different leukocytes populations from circulation into the tumor site [4]; while others are capable of secreting neutrophil chemotactic substances [5]. Neutrophils are the primary source of vascular endothelial growth factor [39], while neutrophils-derived proteinases degrade cytokines and chemokines [40, 41] and remodel the extracellular matrix [42], favoring tumor proliferation, local invasion, angiogenesis and tumor vascularization, promoting metastatic potential [39–43]. Moreover, neutrophil elastase, upon gaining entry to the tumor cells, leads to hyperactivity of the PI3K pathway, accelerating the uncontrolled tumor cell proliferation further [5, 44]. Finally, neutrophils are also capable to degrade basement membrane, mediating local tumor invasion and distant metastases formation [45]. Therefore, increased neutrophils may promote tumor growth and metastasis.

The adaptive immune system is mainly represented by tumor infiltrating lymphocytes comprising CD8+ cytotoxic T-lymphocytes and CD4+ T-helper lymphocytes [46]. Gene profiling analyses of tumor microenvironment in a variety of solid tumors revealed that the majority of them showed a T cell–infiltrated phenotype [47]. During the tumor specific adaptive response, cytotoxic T lymphocytes play a crucial role, inducing production of cytokines [48]. Especially cytokine IFN-γ has a pivotal antitumor role inducing cell cycle arrest and proliferation [34], autophagy-associated apoptosis [49] and antitumor macrophage activity [50]. Noteworthy, neutrophils isolated from early-stage, small-sized tumors are able to stimulate T-cell responses and are cytotoxic to cancer cells [51]. Thus, an increased intratumoral lymphocyte concentration may amplify host systemic inflammatory response to a tumor, fact probably associated with a positive clinical outcome [52, 53]. Pre-treatment lymphocytopenia has been proposed as a surrogate marker of cancer-induced immunosuppression. Various immunosuppressive molecules triggered by activated signaling pathways (STAT, MARK, NF-kB, Wnt/β-catenin) as a result of gene alterations [54] or an inherited T cell triggered adaptive resistance [55], impair activation of helper lymphocytes, promote recruitment of suppressive regulatory T cells and activate the extrinsic pathway of apoptosis, finally impairing lymphocytes homeostasis [56].

An elevated NLR can be the result of either an increase in nominator (neutrophils) or a decrease in denominator (lymphocytes) or both. In tumor microenvironment, an increased neutrophils concentration promotes tumor growth, while a decreased lymphocytes concentration indicates ineffective local tumor control. Thus, an increased microenvironmental NLR may indicate tumor progression, representing a marker of dismal prognosis. Since, all published so far reports, unanimously agree that a high serum NLR is an indicator of unfavorable prognosis, we can postulate that the serum NLR reflects indirectly but accurately the intratumoral inflammation process. Since calculation of intratumoral NLR is neither available in all institutes nor cost-effective, while serum NLR is an easily measured, reproducible and cost-effective marker, serum NLR may hold a great clinical impact in the future.

The present study disclosed that the lowest median NLR value was noticed in T1 tumors (1.88) and was gradually increased up to 2.76 in T4 tumors. Even higher median NLR values were noticed among patients who recurred (2.79), particularly among them who developed distant metastases (3.05). Previous reports [57–59] addressed that the lowest median NLR value had been

| Parameter                      | NLR ≤ 4.7 (n = 260) | NLR > 4.7 (n = 36) | p-value |
|-------------------------------|----------------------|---------------------|---------|
| Local                         | 14                   | 1                   |         |
| Follow up                     |                      |                     |         |
| Alive with recurrence         | 8                    | 0                   | 0.036   |
| Deaths related to the recurrence | 18               | 5                   |         |
| Deaths unrelated to the disease | 35               | 10                  |         |
| Alive                         | 199                  | 21                  |         |
| Probability for overall survival |                  |                     |         |
| Alive                         | 204                  | 21                  | 0.012   |
| Dead                          | 56                   | 15                  |         |
| Probability for recurrence    |                      |                     | NS      |
| No recurrence                 | 234                  | 31                  |         |
| Recurrence                    | 26                   | 5                   |         |

Table 3: Univariate analysis between the two groups of patients, after setting the NLR cutoff value at 4.7 (Continued)
|                | Recurrence | Multivariate Analysis | DFS | Multivariate Analysis |
|----------------|------------|-----------------------|-----|-----------------------|
|                | HR 95% CI  | p value               | HR 95% CI | p value               |
| *NLR*          |            |                       |           |                       |
| ≤ 4.7          | 1          | 1                     | 1         | 1                     |
| > 4.7          | 1.67       | 0.64–4.36             | 0.293     | 1.1                   |
|                |            |                       |           | 0.38–3.21             | 0.862 |
| Gender         |            |                       |           |                       |
| Female         | 1          | 1                     | 1         | 1                     |
| Male           | 1.81       | 0.81–4.04             | 0.15      | 1.73                  |
|                |            |                       |           | 0.76–3.93             | 0.189 |
| Age            |            |                       |           |                       |
| ≤ 72           | 1          | 1                     | 1         | 1                     |
| > 72           | 0.9        | 0.44–1.83             | 0.763     | 1.02                  |
|                |            |                       |           | 0.48–2.17             | 0.949 |
| Primary tumor  |            |                       |           |                       |
| Right colon    | 1          | 1                     | 1         | 1                     |
| Left colon     | 0.84       | 0.29–2.46             | 0.753     | 0.7                   |
|                |            |                       |           | 0.23–2.14             | 0.535 |
| Rectum         | 1.34       | 0.61–2.96             | 0.463     | 1.53                  |
|                |            |                       |           | 0.66–3.55             | 0.316 |
| Grade          |            |                       |           |                       |
| Low            | 1          | 1                     | 1         | 1                     |
| Medium + High  | 1.43       | 0.55–3.73             | 0.464     | 1.98                  |
|                |            |                       |           | 0.73–5.35             | 0.177 |
| *T*            |            |                       |           |                       |
| T1             | 1          | 1                     | 1         | 1                     |
| T2             | 8.74E + 08 | 8.74e + 08–8.74e + 08 | .         | 2.96                  |
|                |            |                       |           | 0.38–22.96            | 0.299 |
| T3             | 1.68e + 09 | 5.79e + 08–4.88e + 09 | 0         | 5.2                   |
|                |            |                       |           | 0.72–37.60            | 0.102 |
| T4             | 3.33e + 09 | 8.89e + 08–1.25e + 10 | 0         | 8.95                  |
|                |            |                       |           | 1.16–69.40            | 0.036 |
| *N*            |            |                       |           |                       |
| N0             | 1          | 1                     | 1         | 1                     |
| N1             | 1.06       | 0.43–2.57             | 0.906     | 1.04                  |
|                |            |                       |           | 0.61–1.79             | 0.884 |
| N2             | 3.60       | 1.54–8.46             | 0.003     | 2.88                  |
|                |            |                       |           | 1.64–5.07             | < 0.001 |
| No lymph nodes yield | | | | |
| ≥ 12           | 1          | 1                     | 1         | 1                     |
| < 12           | 0.55       | 0.13–2.29             | 0.408     | 0.55                  |
|                |            |                       |           | 0.13–2.44             | 0.433 |
| Stage          |            |                       |           |                       |
| Stage I        | 1          | 1                     | 1         | 1                     |
| Stage II       | 3.86       | 0.88–16.99            | 0.074     | 5.14                  |
|                |            |                       |           | 1.14–23.30            | 0.034 |
| Stage III      | 4.81       | 1.10–21.05            | 0.037     | 5.22                  |
|                |            |                       |           | 1.13–24.13            | 0.035 |
| Perineural invasion | | | | |
| No             | 1          | 1                     | 1         | 1                     |
| Yes            | 2.03       | 0.71–5.84             | 0.189     | 0.89                  |
|                |            |                       |           | 0.26–3.05             | 0.848 |
| Vascular invasion | | | | |
| No             | 1          | 1                     | 1         | 1                     |
| Yes            | 4.05       | 1.93–8.49             | 0         | 4.23                  |
|                |            |                       |           | 1.78–10.03            | 0.001 |
| Lymphatic invasion | | | | |
| No             | 1          | 1                     | 1         | 1                     |
| Yes            | 2.42       | 1.04–5.64             | 0.04      | 1.16                  |
|                |            |                       |           | 0.43–3.11             | 0.769 |
|                |            |                       |           | 2.07                  | 1.20–3.59 | 0.009 | 1.48 | 0.77–2.83 | 0.237 |
Table 5  Univariate and Multivariate analysis among factors which might affect the 5-year survival and the overall survival (OS)

|                  | 5-year survival | Overall survival |
|------------------|-----------------|------------------|
|                  | Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis |
| HR               | 95% CI           | p value          | HR               | 95% CI           | p value          | HR               | 95% CI           | p value          |
| NLR              |                 |                  |                 |                  |                  |                 |                  |                  |
| ≤ 4.7            | 1               | 1                | 1               | 1                |                  |                  |                  |                  |
| > 4.7            | 2.58            | 1.45–4.59        | 0.001           | 2.14             | 1.12–4.10        | 0.021           | 2.48             | 1.40–4.40        | 0.002           | 2.11             | 1.11–4.03        | 0.023           |
| Gender           |                 |                  |                 |                  |                  |                  |                  |                  |
| Female           | 1               |                  | 1               |                  |                  |                  |                  |                  |
| Male             | 1.11            | 0.67–1.83        | 0.681           | 1.22             | 0.72–2.04        | 0.459           | 1.18             | 0.72–1.93        | 0.517           | 1.29             | 0.78–2.16        | 0.324           |
| Age              |                 |                  |                 |                  |                  |                  |                  |                  |
| ≤ 72             | 1               |                  | 1               |                  |                  |                  |                  |                  |
| > 72             | 2.05            | 1.25–3.35        | 0.004           | 2.30             | 1.37–3.87        | 0.002           | 2.13             | 1.32–3.46        | 0.002           | 2.41             | 1.45–4.01        | 0.001           |
| Primary tumor    |                 |                  |                 |                  |                  |                  |                  |                  |
| Right colon      | 1               |                  | 1               |                  |                  |                  | 1                |                  |                  |
| Left colon       | 0.88            | 0.42–1.82        | 0.73            | 0.79             | 0.37–1.70        | 0.552           | 0.84             | 0.41–1.72        | 0.627           | 0.76             | 0.35–1.61        | 0.467           |
| Rectum           | 1.35            | 0.79–2.32        | 0.275           | 1.38             | 0.76–2.50        | 0.283           | 1.35             | 0.80–2.29        | 0.262           | 1.37             | 0.77–2.44        | 0.289           |
| Grade            |                 |                  |                 |                  |                  |                  |                  |                  |
| Low              | 1               |                  | 1               |                  |                  |                  | 1                |                  |                  |
| Medium + High    | 1               | 0.55–1.80        | 0.995           | 0.99             | 0.53–1.85        | 0.98            | 1.04             | 0.58–1.87        | 0.891           | 1                | 0.54–1.86        | 0.989           |
| T                |                 |                  |                 |                  |                  |                  |                  |                  |
| T1               | 1               |                  |                  |                  |                  |                  |                  |                  |
| T2               | 2.08            | 0.26–16.63       | 0.491           |                  |                  |                  |                  |                  |
| T3               | 4.25            | 0.59–30.76       | 0.152           |                  |                  |                  |                  |                  |
| T4               | 8.08            | 1.03–63.13       | 0.046           |                  |                  |                  |                  |                  |
| N                |                 |                  |                 |                  |                  |                  |                  |                  |
| N0               | 1               |                  |                  |                  |                  |                  |                  |                  |
| N1               | 1.2             | 0.67–2.15        | 0.546           |                  |                  |                  |                  |                  |
| N2               | 3.68            | 2.04–6.63        | 0                |                  |                  |                  |                  |                  |
| No lymph nodes yield |             |                  |                 |                  |                  |                  |                  |                  |
| ≥ 12             | 1               |                  | 1               |                  |                  |                  | 1                |                  |                  |
| < 12             | 1.6             | 0.84–3.06        | 0.154           | 1.94             | 0.97–3.91        | 0.063           | 1.65             | 0.88–3.07        | 0.116           | 1.95             | 0.99–3.84        | 0.052           |
| Stage            |                 |                  |                 |                  |                  |                  |                  |                  |
| Stage I          | 1               |                  | 1               |                  |                  |                  | 1                |                  |                  |
| Stage II         | 2.35            | 0.97–5.70        | 0.058           | 2.70             | 1.10–6.62        | 0.03            | 2.09             | 0.91–4.80        | 0.08            | 2.41             | 1.04–5.59        | 0.041           |
| Stage III        | 3.4             | 1.43–8.13        | 0.006           | 3.66             | 1.48–9.05        | 0.005           | 3.02             | 1.34–6.80        | 0.008           | 3.27             | 1.40–7.64        | 0.006           |
| Perineural invasion |             |                  |                 |                  |                  |                  |                  |                  |
| No               | 1               |                  | 1               |                  |                  |                  | 1                |                  |                  |
| Yes              | 1.71            | 0.78–3.77        | 0.18            | 0.61             | 0.24–1.54        | 0.297           | 1.66             | 0.76–3.65        | 0.204           | 0.59             | 0.24–1.49        | 0.266           |
| Vascular invasion |             |                  |                 |                  |                  |                  |                  |                  |
| No               | 1               |                  | 1               |                  |                  |                  | 1                |                  |                  |
| Yes              | 2.51            | 1.42–4.43        | 0.001           | 2.36             | 1.17–4.73        | 0.016           | 2.45             | 1.39–4.31        | 0.002           | 2.29             | 1.15–4.57        | 0.019           |
| Lymphatic invasion |             |                  |                 |                  |                  |                  |                  |                  |
| No               | 1               |                  | 1               |                  |                  |                  | 1                |                  |                  |
| Yes              | 2.15            | 1.19–3.89        | 0.011           | 1.41             | 0.69–2.89        | 0.344           | 2.23             | 1.26–3.96        | 0.006           | 1.54             | 0.77–3.08        | 0.217           |
noticed in normal mucosa, increasing gradually in the pathway extending from adenoma to cancer. Therefore, we can propose that host immune system responses with its maximum force at the earliest stage of carcinogenesis, even at the level of precancerous condition, in an attempt to confine tumor locally, subsequently eliminating as cancer cells progressively escape from host immunological surveillance.

In our study, the highest median NLR value was noticed among tumors positive for perineural invasion (3.45), although neural invasion was not disclosed as independent prognostic marker in our multivariate analysis. Perineural invasion is introduced in the seventh edition of TNM [31], as an accessory factor, for poor prognosis. It is believed that perineural invasion is an alternative route of metastatic spread, and it has been associated with poor differentiation, T stage, incidence of metastasis at time of diagnosis, lymphatic, venous invasion and local recurrence. Perineural invasion was also reported to be an independent prognostic factor for 5-year survival and 5-year DFS [60, 61]. We believed that NLR was higher in tumors with perineural invasion as both factors are markers of aggressive phenotype of CRC.

The finding that NLR > 4.7 was directly related to the advanced age of the patients (particularly those over 72 years old) is in agreement to published reports that aging cells create a inflammatory micro-environment more permissive to tumor growth [62].

NLR > 4.7 was found unrelated to the local or distant recurrence, although we tried different cut off values searching for any statistical significance. Cancer cells actively develop different mechanisms to escape tumor immunity. Cancer cells utilize chemokines, which are up-regulated as cancer becomes more malignant, and are key players in cancer cell proliferation and invasiveness, promoting cancer cell metastasis [63]. In response to specific chemokines, different immune cell subsets migrate into the tumor microenvironment and regulate tumor immune responses. Direct and indirect interactions on chemokine pathways may reshape the immune and biological phenotypes of a tumor, making its biological behavior unpredictable and altering its metastatic potential [64].

Even thought NLR > 4.7 was not associated with recurrence, as already stated, high NLR was associated with DFS, this inconsistency in our results, can be explain from the fact that DFS is actually a composite event consisting of either survival or recurrence and the number of recurrent events is low compared to the number of deaths.

The most interesting finding of the present study was that NLR > 4.7 disclosed as an independent dismal prognostic factor for DFS, 5-year survival and overall survival in stage II CRC patients. After adjusting stage for gender, age, location of the primary tumor, differentiation, and presence of perineural, vascular and lymphovascular
Table 6 Multivariate Cox models among factors which might affect the recurrence, the disease free survival (DFS), the 5-year survival and the overall survival (OS) in stage II patients

| Factor                  | Recurrence | DFS        | 5-year survival | Overall Survival |
|-------------------------|------------|------------|-----------------|-----------------|
|                         | HR 95% CI  | p value    | HR 95% CI       | p value         | HR 95% CI       | p value |
| NLR                     |            |            |                 |                 |
| ≤ 4.7                   | 1          | 1          | 1               | 1               |
| > 4.7                   | 1.68 0.37–7.71 0.506 | 2.76 1.07–7.13 0.036 | 3.84 1.39–10.63 0.01 | 3.62 1.33–9.82 0.012 |
| Gender                  |            |            |                 |                 |
| Female                  | 1          | 1          | 1               | 1               |
| Male                    | 1.44 0.44–4.71 0.546 | 1.32 0.63–2.77 0.464 | 1.02 0.44–2.37 0.961 | 1.09 0.48–2.50 0.838 |
| Age                     |            |            |                 |                 |
| ≤ 72                    | 1          | 1          | 1               | 1               |
| > 72                    | 0.88 0.30–2.57 0.811 | 1.64 0.79–3.41 0.183 | 2.33 0.94–5.75 0.066 | 2.56 1.05–6.26 0.039 |
| Primary tumor           |            |            |                 |                 |
| Right colon             | 1          | 1          | 1               | 1               |
| Left colon              | 0.96 0.21–4.40 0.958 | 0.88 0.33–2.35 0.794 | 0.95 0.31–2.94 0.925 | 0.96 0.31–2.95 0.947 |
| Rectum                  | 1.98 0.53–7.41 0.312 | 1.75 0.70–4.39 0.233 | 1.59 0.53–4.76 0.41 | 1.74 0.59–5.11 0.317 |
| Grade                   |            |            |                 |                 |
| Low                     | 1          | 1          | 1               | 1               |
| Medium + High           | 1.67 0.37–7.58 0.506 | 1.34 0.53–3.40 0.541 | 1.31 0.45–3.80 0.625 | 1.36 0.47–3.93 0.569 |
| No lymph nodes yield    |            |            |                 |                 |
| ≥ 12                    | 1          | 1          | 1               | 1               |
| < 12                    | 1.82 0.66–5.07 0.249 | 2.76 0.90–8.45 0.075 | 2.4 0.80–7.19 0.117 | |
| Perineural invasion     |            |            |                 |                 |
| No                      | 1          | 1          | 1               | 1               |
| Yes                     | 0.49 0.08–2.85 0.426 | 0.57 0.09–3.78 0.562 | 0.63 0.10–4.04 0.624 | |
| Vascular invasion       |            |            |                 |                 |
| No                      | 1          | 1          | 1               | 1               |
| Yes                     | 2.65 0.53–13.18 0.234 | 2.09 0.71–6.13 0.182 | 2.28 0.66–7.89 0.192 | 2.22 0.65–7.58 0.205 |
| Lymphatic invasion      |            |            |                 |                 |
| No                      | 1          | 1          | 1               | 1               |
| Yes                     | 0.93 0.10–8.70 0.953 | 2.3 0.75–7.02 0.145 | 2.06 0.55–7.69 0.284 | 2.12 0.58–7.80 0.257 |

Table 7 Correlation between NLR and DFS, 5-year survival and OS by stage, after adjusting it by gender, age, location of the primary tumor, differentiation as well as presence of perineural, vascular, and lymphovascular invasion

| Stage | DFS | 5-year survival | Overall Survival |
|-------|-----|-----------------|-----------------|
|       | HR 95% Confidence Interval | p value | HR 95% Confidence Interval | p value | HR 95% Confidence Interval | p value |
| Stage I | NLR > 4.7 | 1.60 0.19–13.41 | 0.663 | 2.06 0.23–18.18 | 0.514 | 1.85 0.22–15.88 | 0.572 |
| Stage II | NLR > 4.7 | 2.85 1.21–6.73 | 0.017 | 4.06 1.66–9.93 | 0.002 | 4.07 1.67–9.91 | 0.002 |
| Stage III | NLR > 4.7 | 1.33 0.54–3.28 | 0.537 | 1.28 0.50–3.22 | 0.605 | 1.27 0.50–3.18 | 0.612 |
invasion, NLR > 4.7 was isolated as dismal prognostic factor only for stage II patients.

According to the American Joint Committee on Cancer (AJCC), stage II CRC includes three subcategories: stage IIA (T3 N0), stage IIB (T4aN0) and stage IIC (T4bN0). Seventy five percent of stage II CRC patients can be cured with surgery alone, not experiencing any further recurrence, while the remaining 25% will develop recurrence in the future [65]. The definition of whom among the CRC stage II patients constitute a ‘high-risk’ subpopulation, which will be favored by adjuvant chemotherapy is not clearly defined in the TNM staging system and there is no clear consensus in the literature [66].

European Society for Medical Oncology (ESMO) recommends adjuvant chemotherapy for those individuals who fulfill at least one of the following criteria: T4 tumors, poorly differentiated tumors, tumors with vascular, lymphatic or perineural invasion, inadequate sample of lymph nodes (< 12) and bowel perforation or bowel obstruction at presentation [67].

The National Comprehensive Cancer Network (NCCN) furthermore recommends adjuvant chemotherapy for patients with inadequate or positive resection margins, with tumors characterized as MSI-L or MSS, with no significant comorbidities and anticipated life expectancy [66]. Stage II MSI-H CRC tumors do not benefit from adjuvant therapy [68].

The prognostic significance of NLR has also been examined in the subgroup of stage II CRC patients. Ding et al. [69] disclosed that an elevated NLR was related to a worse 5-year survival. Hung et al. [70] addressed that an elevated NLR was an independent predictor for OS but not for DFS because the patients of his study with an elevated NLR tended to have an increased risk of death from other causes and an elevated NLR was linked with some stronger risk factors such as T4b cancers, tumor obstruction or tumor perforation. Two reports from the same Institute [71, 72], concluded that an elevated NLR was related to a decreased OS and a decreased time-to-relapse, particularly in the group of patients who underwent curative surgery alone compared to them who underwent adjuvant chemotherapy. The authors concluded that an elevated NLR may be a negative prognostic marker, and that such high-risk patients may benefit from adjuvant chemotherapy. The most recent report is coming from Turner et al [15] who found that the combination of low intratumoral chronic inflammatory cells density with high serum NLR level, served a poor outcome in terms of recurrence-free survival and OS for stage II CRC patients, finally suggesting that in this particular subgroup of patients, adjuvant chemotherapy might be considered.

After adjusting stage by gender, age, location of the primary tumor, differentiation, the presence of perineural, vascular and lymphovascular invasion, the present study isolated NLR > 4.7 as an independent dismal prognostic factor only for stage II CRC patients. We hypothesize that in stage III patients, the well-known prognostication of the metastatically infiltrated lymph nodes [73, 74] represents the strongest factor finally defining the poorer outcome. The new finding that in stage II CRC patients an elevated NLR may be by itself an independent dismal prognostic factor should be evaluated further in order to be determined its prognostic significance (if any) and its possible clinical implications.

Conclusion
The present study concluded that in patients with localized CRC, a pretreatment NLR above 4.7 is a dismal prognostic factor for disease free survival (DFS), 5-year survival and overall survival (OS). The dismal prognostic effect of NLR is magnified in Stage II CRC patients.

Abbreviations
AJCC: American Joint Committee on Cancer; CI: Confidence Interval; CRC: Colorectal Cancer; CRP: C-reactive protein; CT: Computer tomography; DFS: Disease Free Survival; ESMO: European Society for Medical Oncology; HR: Hazard Ratio; INF-γ: Interferon gamma; IQR: Interquartile Range; MMR: Mismatch repair; MRI: Magnetic resonance imaging; MSI: Microsatellite instability; NCCN: National Comprehensive Cancer Network; NLR: Neutrophil to lymphocyte ratio; OS: Overall Survival; ROC: Receiver Operating Characteristic; TNM: TNM Classification of Malignant Tumors

Acknowledgments
No acknowledgments.

Funding
No funding.

Availability of data and materials
The dataset used and analysed during the present study is available from the corresponding author upon reasonable request.

Authors’ contributions
EF, IK, AA, EP and JG enrolled patients; ND, IK and JG designed the study; EF, IK, AA, EP and JG analyzed the data; EF made useful comments and corrections; ND and JG wrote the article; JG made the final approval. All authors have read and approved the final version for publication.

Ethics approval and consent to participate
The study was approved by the ethics committee of the LAIKO Hospital. All participants signed informed consent forms.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 7 July 2018 Accepted: 5 November 2018 Published online: 03 December 2018

References
1. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138:2059–72.
2. Marks KM, West NP, Morris E, Quirke P. Clinicopathological, genomic and immunological factors in colorectal cancer prognosis. Br J Surg. 2018;105: e99–e109.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
4. Pedrazzani C, Mantovani G, Fernandes E, Bagante F, Luca Salvagno G, Surin N, et al. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer. Sci Rep. 2017;7:1494.
5. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71:2411–6.
6. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 2007;7:139–47.
7. Yin J, Markert JM, Levenson JW. Modulation of the Intratumoral immune landscape by oncolytic herpes simplex virus Virotherapy. Front Oncol. 2017;7:136.
8. Lee WS, Park S, Lee WY, Yun SH, Chun HK. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer. 2010;116:1588–99.
9. Valka J, Lotic MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641–8.
10. DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of cancer initiation and progression. Nat Rev Cancer. 2014;14:314–27.
11. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Cancer. 2001;1:139–47.
12. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical mediator of tumour growth promotion. Nat Rev Cancer. 2002;2:329–40.
13. Turnier N, Wong HL, Templeton A, Tripathy S, Whiti Rogers T, Croxford M, et al. Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. Int J Cancer. 2016;138:671–8.
14. Roxburgh CS, McClelland DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014;110:1409–12.
15. McClelland DC, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014;16:717–27.
16. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg. 2009;249:788–93.
17. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Surg. 2009;175:2138–45.
18. Turner N, Wong HL, Templeton A, Tripathy S, Whitli Rogers T, Croxford M, et al. Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. Int J Cancer. 2016;138:671–8.
19. Roxburgh CS, McClelland DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014;110:1409–12.
20. McClelland SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014;16:717–27.
21. Yamada K, Shibusawa M, Otani H, Nagahara H, Ikeya T, Iseki Y, et al. Inflammation-based factors and prognosis in patients with colorectal cancer. J Cancer Res Ther. 2016;12:582–9.
22. Zhang J, Zhang HY, Li J, Shao XY, Zhang CX. The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:68387–46.
23. Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014;134:2403–13.
24. Tsai PL, Su WJ, Leung WH, Lai CT, Liu CK. Neutrophil-lymphocyte ratio and CEA level as prognostic and predictive factors in colorectal cancer: a systematic review and meta-analysis. J Cancer Res Ther. 2016;12:2582–9.
25. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014;134;2403–13.
26. Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour invasion and angiogenesis. J Pathol. 2004;204:287–93.
27. Grizzi F, Basso G, Borroni EM, Cavaliere T, Bianchi P, Stifter S, et al. Evolution of innate lymphoid cells in tumor invasion and angiogenesis. Cell. 2001;189:197–206.
28. Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour invasion and angiogenesis. J Pathol. 2004;204:287–93.
29. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, et al. Neutrophil elastase-mediated degradation of Integrin-1 accelerates lung tumour growth. Nat Med. 2010;16:219–23.
30. Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014;134:2403–13.
31. McCourt M, Wang JH, Sookhal S, Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg. 1999;134:1235–2.
32. Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol. 2006;6:541–50.
33. Grivennikov SI, Greten FR, Karin M. Inflammation, and cancer. Cell. 2010;140:839–93.
34. Sharmapian S, Schwartz JD, Pocock BJ, Monea S, Whiting D, Marcus SG, et al. Activation of progranulinase-1 (a-MMP-2) by neutrophil elastase, cathespin G and proteinase-3: a role for inflammatory cells in tumor invasion and angiongenesis. J Cell Physiol. 2001;189:197–206.
35. Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol. 2009;90:22–31.
36. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, et al. Neutrophil elastase-mediated degradation of Integrin-1 accelerates lung tumour growth. Nat Med. 2010;16:219–23.
37. Huh SJ, Liang S, Sharma A, Dong C, Robertson GP. Transient entrapped circulating tumour cells interact with neutrophils to facilitate lung metastasis development. Cancer Res. 2010;70:6071–82.
38. Grizzi F, Basso G, Borroni EM, Cavaliere T, Bianchi P, Stifter S, et al. Evolution of innate lymphoid cells in tumor invasion and angiogenesis. Cell. 2001;189:197–206.
39. Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. J Pathol. 2004;204:287–93.
40. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, et al. Neutrophil elastase-mediated degradation of Integrin-1 accelerates lung tumour growth. Nat Med. 2010;16:219–23.
41. Sharmapian S, Schwartz JD, Pocock BJ, Monea S, Whiting D, Marcus SG, et al. Activation of progranulinase-1 (a-MMP-2) by neutrophil elastase, cathespin G and proteinase-3: a role for inflammatory cells in tumor invasion and angiongenesis. J Cell Physiol. 2001;189:197–206.
42. Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. J Pathol. 2004;204:287–93.
43. Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. J Pathol. 2004;204:287–93.
51. Kiss M, Van Gassen S, Movahedi K, Saesy Y, Laoui D. Myeloid cell heterogeneity in cancer: not a single cell alike. Cell Immunol. 2018. https://doi.org/10.1016/j.cellimm.2018.02.008.

52. Kennelly RP, Murphy B, Larkin JD, Mehigan BJ, McCormick PH. Activated systemic inflammatory response at diagnosis reduces lymph node count in colonic carcinoma. World J Gastrointest Oncol. 2016;8:623–8.

53. Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y, Hirakawa K. A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res. 2013;33:3291–4.

54. Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, et al. The mechanisms of cancer immunescape and development of overcoming strategies. Int J Hematol. 2011;93:294–300.

55. Yaguchi T, Kawakami Y. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int Immunol. 2016;28:393–9.

56. Joseph N, Dovedi SJ, Thompson C, Lyons J, Kennedy J, Elliott T, et al. Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer. Ann Oncol. 2016;27:294–9.

57. Zhou WW, Chu YP, An GY. Significant difference of neutrophil-lymphocyte ratio between colorectal cancer, adenomatous polyp and healthy people. Eur Rev Med Pharmacol Sci. 2017;21:5386–91.

58. Emir S, Aydin M, Can G, Bali I, Yildirim O, Oznur M, et al. Comparison of colorectal neoplastic polyps and adenocarcinoma with regard to NLR and PLR. Eur Rev Med Pharmacol Sci. 2015;19:3613–8.

59. Ucmak F, Tuncel ET. Relationship between lesions in adenomatous polyp-dysplasia-colorectal cancer sequence and neutrophil-to-lymphocyte ratio. Med Sci Monit. 2016;22:4536–41.

60. van Wyk HC, Going J, Horgan P, McMillan DC. The role of perineural invasion in predicting survival in patients with primary operable colorectal cancer: a systematic review. Crit Rev Oncol Hematol. 2017;112:11–20.

61. Knijn N, Moog SC, Tenenstorp S, Simmer F, Nagtegaal ID. Perineural invasion is a strong prognostic factor in colorectal cancer: a systematic review. Am J Surg Pathol. 2016;40:103–12.

62. Owyong M, Efe G, Abbasi AJ, Sitarama V, Plaks V. Overcoming barriers of age to enhance efficacy of cancer immunotherapy: the clout of the extracellular matrix. Front Cell Dev Biol. 2018;6:19.

63. Itatani Y, Kawada K, Inamoto S, Yamamoto T, Ogawa R, Taketo MM, Sakai Y. The role of chemokines in promoting colorectal cancer invasion/metastasis. Int J Mol Sci. 2016;17. https://doi.org/10.3390/ijms17050643.

64. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559–72.

65. Lavery IC, De Campos-Lobato LF. How to evaluate risk and identify stage II patients requiring referral to a medical oncologist: a surgeon’s perspective. Oncology (Williston Park). 2010;24:14–6.

66. Meyers BM, Cosby R, Quereshy F, Jonker D. Adjuvant chemotherapy for stage II and III colon cancer following complete resection: a Cancer Care Ontario systematic review. Clin Oncol (R Coll Radiol). 2017;29:459–65.

67. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, Arnold D. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64–72.

68. NCCN. Guidelines Clinical Practice Guidelines in Oncology (NCCN Guidelines) Version 2 2018. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 2 June 2018.

69. Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, et al. Elevated preoperative neutrophil-to-lymphocyte ratio predicts risk of recurrence following curative resection for stage II A colon cancer. Int J Colorectal Dis. 2010;25:1427–33.

70. Hung HY, Chen JS, Yeh CY, Changchien CR, Tang R, Hsieh PS, et al. Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis. 2011;26:1059–65.

71. Absenger G, Szkandera J, Pichler M, Stotz M, Amringer F, Weissmueller M, et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer. 2013;109:395–400.